ADA is here and the Breakthrough T1D team is on site! Day one came with some very exciting news from Vertex on the trials surrounding their drug Zimislecel, also known as VX880. Our Chief Scientific Officer, Dr. Sanjoy Dutta, breaks down the latest updates on where the trial stands one year later and what happens next. A few highlights from their announcement: ☑️ 10/12 participants no longer need external insulin therapy and all 12 participants are making their own insulin a year after receiving

The American Dental Association is working hard to provide support and guidance to dentists at this challenging time. Because the COVID-19 situation is evolving rapidly, visit bit.ly/ADAupdates for ongoing updates, on-demand access to digital events, safety and clinical guidance, practice management content, and more. | American Dental Association